These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7570065)

  • 1. Cytokines and their antagonists in myeloid disorders.
    Estrov Z; Kurzrock R; Talpaz M
    Semin Hematol; 1995 Jul; 32(3):220-31. PubMed ID: 7570065
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic inflammatory joint diseases: natural inhibitors of interleukin 1 and tumor necrosis factor alpha.
    Dayer JM
    J Rheumatol Suppl; 1991 Feb; 27():71-5. PubMed ID: 2027136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
    Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman JU; Talpaz M
    Exp Hematol; 1993 Jan; 21(1):80-5. PubMed ID: 8417962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines and anti-cytokines in inflammatory rheumatism].
    Dayer JM
    Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):173S-180S. PubMed ID: 7858569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
    Wetzler M; Estrov Z; Talpaz M; Kim KJ; Alphonso M; Srinivasan R; Kurzrock R
    Cancer Res; 1994 Apr; 54(7):1837-42. PubMed ID: 8137298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interleukin-1 in disease.
    Dinarello CA; Wolff SM
    N Engl J Med; 1993 Jan; 328(2):106-13. PubMed ID: 8439348
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytokine and anti-cytokine strategies in inflammatory reaction modulation.
    Delannoy I; Lekeux P; Miossec P
    Vet Res; 1993; 24(6):449-67. PubMed ID: 8111428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
    Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inflammatory cytokines].
    Mantovani A
    Recenti Prog Med; 2000 Sep; 91(9):422-4. PubMed ID: 11021162
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemias and plasma cell myeloma.
    Wiernik PH
    Cancer Chemother Biol Response Modif; 1997; 17():390-407. PubMed ID: 9551222
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine expression of T cells in chronic myeloid leukemia.
    Liu Y; Kleine HD; Engel H; Andreeff M
    Chin Med J (Engl); 2000 Mar; 113(3):232-5. PubMed ID: 11775253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemias and plasma cell myeloma.
    Wiernik PH
    Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J; Redlich K; Schett G; Smolen JS
    Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats.
    Takeda R; Suzuki E; Satonaka H; Oba S; Nishimatsu H; Omata M; Fujita T; Nagai R; Hirata Y
    Circulation; 2005 Mar; 111(11):1398-406. PubMed ID: 15781751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia.
    McKenna SJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4.
    Preisler HD; Li B; Yang BL; Huang RW; Devemy E; Venugopal P; Tao M; Chopra H; Gregory SA; Adler S; Sivaraman S; Toofanfard P; Jajeh A; Galvez A; Robin E
    Clin Cancer Res; 2000 Mar; 6(3):807-12. PubMed ID: 10741700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.